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Specific HLA class I alleles are strongly associ-
ated  with  HIV-1  disease  outcomes,  and  the 
identification  of  mechanisms  accounting  for 
their impact on HIV-1 disease progression pro-
vides a premier opportunity to analyze compo-
nents of protective immunity against HIV-1 and 
how the immune system can be effectively ma-
nipulated in a therapeutic manner (Carrington 
and O’Brien, 2003). Remarkably, prior studies 
(Gao et al., 2001) have found that HLA-B*35-
Px subtypes (HLA-B*3502, B*3503, B*3504, 
and  B*5301)  are  associated  with  accelerated 
HIV-1  disease  courses,  in  contrast  to  HLA-
B*35-PY (HLA-B*3501 and B*3508) subtypes, 
which do not have any detectable impact on 
HIV-1 disease progression, even though B*35-
PY and B*35-Px subtypes can differ by as few 
as one amino acid. Because HLA class I alleles 
restrict cytotoxic T lymphocyte (CTL) epitopes, 
the differential disease progression between the 
B*35-PY and B*35-Px groups was proposed 
to depend on divergent CTL responses with a 
potential skewing of B*35-Px–restricted HIV-
1–specific CTL responses toward nonfunctio-
nal (decoy) epitopes. Recent studies, however, 
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A subset of HLA-B*35 alleles, B*35-Px, are strongly associated with accelerated HIV-1 
disease progression for reasons that are not understood. Interestingly, the alternative set of 
B*35 subtypes, B*35-PY, have no detectable impact on HIV-1 disease outcomes, even 
though they can present identical HIV-1 epitopes as B*35-Px molecules. Thus, the differen-
tial impact of these alleles on HIV-1 disease progression may be unrelated to interactions 
with HIV-1–specific CD8+ T cells. Here, we show that the B*35-Px molecule B*3503 binds 
with greater affinity to immunoglobulin-like transcript 4 (ILT4), an inhibitory MHC class I 
receptor expressed on dendritic cells, than does the B*35-PY molecule B*3501, even though 
these two B*35 molecules differ by only one amino acid and present identical HIV-1 epi-
topes. The preferential recognition of B*3503 by ILT4 was associated with significantly 
stronger dendritic cell dysfunction in in vitro functional assays. Moreover, HIV-1–infected 
carriers of B*3503 had poor dendritic cell functional properties in ex vivo assessments 
when compared with carriers of the B*3501 allele. Differential interactions between HLA 
class I allele subtypes and immunoregulatory MHC class I receptors on dendritic cells thus 
provide a novel perspective for the understanding of MHC class I associations with HIV-1 
disease progression and for the manipulation of host immunity against HIV-1.
© 2009 Huang et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Lin HLA-DR+CD11c+ dendritic cells from untreated HIV-
1–infected individuals with chronic progressive HIV-1 infec-
tion. As determined by flow-cytometric studies, we found 
that B*3503 (Px) complexes have significantly higher bind-
ing intensities to dendritic cells, compared with the respec-
tive B*3501 (PY) complexes refolded with identical epitopes 
(Fig. 1, A and B). These binding interactions were almost 
completely abrogated after incubation with polyclonal anti-
bodies that specifically block ILT4 and have no detectable 
cross-reactivity  with  alternative  receptors  from  the  LILR 
family (Fig. 1, A and B). In contrast, antibodies blocking 
ILT2, an alternative HLA class I receptor expressed on den-
dritic cells (Colonna et al., 1997), had no effects on tetramer 
binding  to  dendritic  cells  (unpublished  data).  To  confirm 
these flow-cytometric findings, we investigated the binding 
interactions between the recombinant tetramers (two inde-
pendently produced sets obtained from the National Insti-
tutes  of  Health  Tetramer  Core  Facility)  and  recombinant 
ILT4 directly by cell- and label-free surface plasmon reso-
nance (SPR) analysis. These experiments indicated that the 
binding affinity between B*3503 (Px)-NY9 tetramers and 
ILT4 was higher compared with the corresponding interac-
tion between ILT4 and B*3501 (PY)-NY9 tetramers. Nota-
bly,  SPR  experiments  also  showed  that  the  PY9  epitope 
bound to ILT4 only when presented by the HLA-B*3503 
molecule (Fig. 1 C), consistent with our flow cytometry data 
indicating  no  detectable  ILT4-mediated  binding  of  the 
B*3501-PY9 tetramer to dendritic cells (Fig. 1, A and B). To 
test if alternative HLA-B*35-Px subtypes also mediate en-
hanced binding to ILT4, we used a recombinant B*3502 tet-
ramer refolded with the described PY9 epitope. Similar to 
the B*3503-PY9 tetramer, this molecule had significantly in-
creased binding intensity to ILT4 compared with the B*3501-
PY9 tetramer, as determined by flow cytometric and SPR 
experiments (Fig. S1, A and B). Overall, these data indicate 
that although presenting identical epitopes as B*3501 (PY), 
B*3503/02 (Px) molecules have preferential binding proper-
ties to ILT4, and may thus cause increased inhibitory im-
pulses on dendritic cells.
To determine if the preferential binding of B*3503 (Px) 
complexes to ILT4 translates into a functional inhibition of 
dendritic cells, we used in vitro mixed lymphocyte reactions 
(MLRs)  with  monocyte-derived  dendritic  cells  (MDDCs) 
that had previously been matured in the presence of the re-
spective  B*3503  (Px)  or  B*3501  (PY)  tetramers  refolded 
with identical epitopic peptides. ILT4 surface expression dur-
ing this maturation process was similar in both groups, irre-
spective of whether B*3503 or B*3501 tetramers had been 
added. Using MDDCs from 11 donors, these studies showed 
that after dendritic cell maturation in the presence of HLA-
B*3503  tetramers,  proliferation  of  allogeneic  CD4+  and 
CD8+ T cells was significantly impaired, compared with exp-
eriments in which MDDCs were matured while exposed to 
B*3501 tetramers refolded with the identical epitopes (Fig. 2, 
A and D). Notably, after specific down-regulation of ILT4 su-
rface expression on MDDCs using targeted siRNA-mediated 
found no positive evidence for this (Jin et al., 2002; Streeck 
et al., 2007), and the mechanisms accounting for the differ-
ential influence of HLA-B*35 subtypes on HIV-1 disease pro-
gression and the specific negative impact of B*35-Px subtypes 
remain  unknown  (Goulder  and Watkins,  2008).  Notably, 
HLA-B*35-Px and -PY subtypes can present identical HIV-1   
CTL epitopes, and thus provide a unique model to study 
HLA class I–mediated immune activity against HIV-1 inde-
pendently of the presented peptides.
In addition to their role as immunogens for the generation 
of antigen-specific CTLs, peptide–MHC class I complexes 
have  important  regulatory  functions  that  are  mediated  by 
binding to immunomodulatory MHC class I receptors such as 
killer immunoglobulin-like receptors (KIRs; Lanier, 1998) or 
leukocyte  immunoglobulin-like  receptors  (LILRs;  Brown   
et al., 2004). LILRB2, also termed immunoglobulin-like tran-
script 4 (ILT4), is a prominent inhibitory myelomonocytic 
MHC class I receptor (Colonna et al., 1998) that is expressed 
primarily  on  professional  antigen-presenting  cells,  such  as 
monocytes and dendritic cells, and is strongly up-regulated 
during chronic HIV-1 infection (Vlad et al., 2003). Recent 
data  suggest  that  interactions  between  ILT4  and  peptide–
MHC class I complexes can critically depend on the presented 
antigenic peptide or the respective presenting MHC class I 
molecule (Shiroishi et al., 2006; Lichterfeld et al., 2007), rais-
ing the possibility that HLA class I alleles could impact HIV-1 
disease progression by differentially affecting ILT4-mediated 
immunomodulatory properties of dendritic cells.
In the present study, we tested this hypothesis by deter-
mining the binding interactions between ILT4 and HLA-
B*3503 (a B*35-Px molecule) as well as -B*3501 (a B*35- 
PY molecule) in the context of identical CTL epitopes that   
are presented by both HLA-B*35 molecules. We found that 
B*3503  binds  ILT4  significantly  stronger  than  does  the 
B*3501 molecule, independently of the presented epitopes. 
This corresponded to higher degrees of ILT4-mediated den-
dritic cell dysfunction mediated by B*3503 in vitro, and a 
striking functional impairment of dendritic cells in HIV-1–
infected carriers of the B*3503 allele in ex vivo assessments. 
Overall, these data suggest that allele-specific interactions be-
tween HLA class I molecules and their receptors on dendritic 
cells may significantly impact HIV-1 disease outcomes and 
thus provide a novel perspective for the understanding of   
immunoregulatory functions of HLA class I alleles in the 
pathogenesis of HIV-1 infection.
RESULTS AND DISCUSSION
To test whether HIV-1 CTL epitopes presented by alterna-
tive B*35 subtypes are differentially recognized by the inhib-
itory myelomonocytic receptor ILT4 on dendritic cells, we 
focused on two CTL epitopes that are both targeted in HIV-
1–infected carriers of HLA-B*35-Px or -B*35-PY subtypes: 
the NY9 epitope (NPDIVIYQY) in RT and the PY9 epitope 
(PPIPVGDIY) in Gag. We used recombinant, fluorophore-
labeled HLA-B*3501 (PY) and -B*3503 (Px) tetramers re-
folded with the respective epitopes to stain peripheral blood JEM VOL. 206, December 21, 2009  2961
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Figure 1.  Preferential recognition of HIV-1 CTL epitope/HLA-B*3503 (Px) complexes by the inhibitory myelomonocytic receptor ILT4.  
(A and B) Binding of HLA-B*3503 (Px) and -B*3501 (PY) tetramers refolded with two different CTL epitopes to PBMCs, as determined by flow cytometry. 
ILT4-specific antibodies were able to fully abrogate tetramer binding to dendritic cells. (A) Histograms for one representative example are shown.  
(B) Cumulative flow cytometry data from HIV-1–infected patients (n = 8) (two-tailed paired Student’s t test). (C) SPR sensograms reflecting the control 
surface-subtracted interactions between recombinant ILT4 and immobilized HLA-B*3503 or -B*3501 tetramers refolded with the indicated epitope. ILT4 
was injected in five serial twofold dilutions from a starting concentration of 1 µM. The respective apparent steady-state equilibrium constant (KD) is indi-
cated. One representative experiment out of three is shown.2962 Divergent binding of HLA-B*35 alleles to ILT4 | Huang et al.
Figure 2.  Allostimulatory dysfunction of MDDCs mediated by interactions between HLA-B*35-Px complexes and ILT4. (A and D) Allogeneic 
CD4+ and CD8+ T cell proliferation after in vitro stimulation with MDDCs matured in the presence of HLA-B*3503 (Px) or -B*3501 (PY) tetramers refolded 
with the indicated epitopes at a DC/T cell ratio of 1:50. Dot plots from one representative experiment are shown in A; cumulative data from n = 11 study 
subjects are shown in D (two-tailed paired Student’s  t test). (B) ILT4 surface expression on MDDCs after electroporation with ILT4-specific or unspecific 
control siRNA. (C and E): Allogeneic T cell proliferation after stimulation with MDDCs matured with the indicated HLA-B*3503 or -B*3501 tetramers in the 
presence of siRNA-mediated down-regulation of ILT4. Dot plots from one representative experiment are shown in C; cumulative data from n = 4 study 
subjects are shown in E (two-tailed paired Student’s t test).JEM VOL. 206, December 21, 2009  2963
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In addition to allostimulatory activities, we also assessed 
cytokine secretion and phenotypic characteristics of dendritic 
cells induced by the HLA-B*3503 (Px) and -B*3501 (PY) 
tetramers. These experiments showed that dendritic cell mat-
uration in the presence of HLA-B*3503 (Px) tetramers re-
sulted in reduced expression of the costimulatory molecule 
CD86 and the maturation marker HLA-DR, as well as in 
decreased  secretion  of  IL-12p70  and  IL-6,  two  cytokines   
gene knockout (Fig. 2 B), these inhibitory effects were 
abrogated and no difference was observed between the 
functional properties of MDDCs exposed to either the 
B*3503 or B*3501 tetramers (Fig. 2, C and E). Impor-
tantly,  decreased  allostimulatory  properties  of  dendritic 
cells were also observed after dendritic cell exposure to 
the  alternative  HLA-B*35-Px  tetramer,  B*3502-PY9 
(Fig. S1 C).
Figure 3.  Decreased maturation and cytokine production of MDDC mediated by interactions between HLA-B*3503 complexes and ILT4.  
(A) Expression of the costimulatory molecule CD86 and the maturation marker HLA-DR on MDDC after maturation in the presence of HLA-B*3503 (Px) or 
-B*3501 (PY) tetramers refolded with the indicated epitopes. Cumulative data from n = 12 study subjects are shown (two-tailed paired Student’s t test). 
Colors reflect samples identity. (B and C) Cytokine production of MDDC after maturation and exposure to HLA-B*3503 or -B*3501 tetramers refolded with 
NY9 epitope. Dot plots from one representative experiment are shown in B; cumulative data from n = 4 study subjects are shown in C (two-tailed paired 
Student’s t test).2964 Divergent binding of HLA-B*35 alleles to ILT4 | Huang et al.
Figure 4.  Impaired dendritic cell function in HIV-1–infected carri-
ers of HLA-B*3503 (Px) alleles. Data show allogeneic T cell prolifera-
tion after stimulation with dendritic cells isolated from peripheral blood 
of HAART-naive HIV-1–infected carriers of HLA-B*3503 (Px) or -B*3501 
(PY) at the indicated DC/T cell ratios. (A) Data from one representative 
experiment; (B) summarized data from n = 6 B*3501 carriers and n = 7 
B*3503 carriers (two-tailed Mann-Whitney U test).
involved in dendritic cell maturation (Fig. 3). Collectively, 
these experiments show that stronger interactions between 
B*35-Px subtypes and ILT4 can lead to functional impair-
ment of dendritic cells.
Based on these in vitro findings, we next tested for ex 
vivo functional differences between dendritic cells from car-
riers of HLA-B*3503 (Px) or -B*3501 (PY). For this pur-
pose, we conducted MLRs with dendritic cells isolated from 
the peripheral blood of HAART-naive HIV-1–infected car-
riers of HLA-B*3503 or -B*3501 recruited from a multi-
center cohort of hemophiliac seroconverters (Goedert et al., 
1989). HIV-1 viral loads (mean of 52,335 vs. 115,535 copies/ 
ml, P = 0.39) and CD4 cell counts (mean of 21 vs. 15%, P = 
0.23) did not differ significantly between carriers of HLA-
B*3501 (PY) and -B*3503 (Px), despite a longer duration of 
HIV-1 infection in the HLA-B*3501 (PY) group (mean of 
13 vs. 10 yr). Except for the expression of different HLA-
B*35 subtypes, these patients did not differ significantly in 
their  patterns  of  expressed  HLA  class  I  molecules.  Using 
MLR assays, we observed a statistically significant defect of 
allogeneic T cell proliferation with myeloid DCs from carri-
ers of B*3503 as compared with carriers of B*3501 (Fig. 4, A 
and B). This difference increased with escalating DC/T cell 
ratios (Fig. 4 B) and was highly reproducible with allogeneic 
T cells from an alternative T cell donor (inter-assay correla-
tion R = 0.9015, P = 0.0004). Notably, the difference be-
tween  dendritic  cell  function  in  these  patients  with  long 
histories  of  HIV-1  infection  was  substantially  more  pro-
nounced  than  the  differential  function  of  dendritic  cells 
achieved by B*3503 (Px) and B*3501 (PY) tetramers in our 
short-term tissue culture experiments.
Of all HLA class I alleles, the B*35-Px grouping of alleles 
plays a unique role in HIV-1 immunopathogenesis, as it rep-
resents the strongest identified predictor of an accelerated 
HIV-1 disease progression (Carrington et al., 1999; Gao et al.,   
2001; O’Brien et al., 2001). The reason for this negative im-
pact on HIV-1 disease courses has been a matter of intense 
debate, but how an HLA class I subtype can substantially 
worsen HIV-1 disease outcomes has remained unclear thus 
far. Notably, HIV-1–infected carriers of B*35-Px subtypes 
progress to AIDS faster than individuals with homozygous 
HLA-B alleles (Gao et al., 2001, 2005), and these subtypes 
are therefore likely to actively mediate a negative effect in 
HIV-1  pathogenesis,  rather  than  simply  representing  the 
functional equivalent of a null allele at the HLA-B locus. 
Prior studies have related HLA class I–mediated effects on 
HIV-1 disease outcomes to the restriction of specific viral 
epitopes  putatively  mediating  higher  susceptibility  to  host 
immune activity (Frahm et al., 2005; Stewart-Jones et al., 
2005; Kiepiela et al., 2007; Loffredo et al., 2009). However, 
it appears that specific HLA class I alleles associated with di-
vergent  clinical  outcomes  of  HIV-1  infection  can  restrict 
CTL epitopes in viral regions that are overlapping or imme-
diately adjacent to one another (Brander and Goulder, 2000). 
This is particularly true in the setting of B*35-Px and -PY 
subtypes, which can present identical viral epitopes despite 
their opposing association with HIV-1 disease progression. 
Overall, this suggests that HLA class I alleles can affect im-
mune activity against HIV-1 by mechanisms other than CTL 
epitope presentation and interactions with T cell receptors 
(TCRs) on HIV-1–specific CD8+ T cells.
The data presented here add a novel dimension to this con-
cept by highlighting previously unrecognized, CTL epitope–
independent immunoregulatory effects of HLA class I alleles 
that are mediated by their interactions with the myelomono-
cytic MHC class I receptor ILT4 and lead to functional changes 
of dendritic cells. Our data indicate that inhibitory impulses 
resulting from preferential recognition of B*3503 (Px) sub-
types by ILT4 may lead to substantial dendritic cell dysfunc-
tion, and are thus likely to play a key role within the molecular JEM VOL. 206, December 21, 2009  2965
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GM-CSF (Amgen) for 5 d in 1% human plasma medium. On d 5, immature 
myelomonocytic cells were harvested using Hanks-based Cell-disassociation 
buffer (Invitrogen), incubated with HLA-B*35-Px or -PY tetramers for 4 h, 
and then matured using a previously described cytokine cocktail containing 
IL-1, TNF-, PGE-2, and IL-6 (Kavanagh et al., 2006). After 16 h, cells 
were either stained with surface antibodies against CD86 and HLA-DR and 
processed to immediate flow cytometric analysis for phenotypic character-
ization, or mixed with allogenic CFSE-labeled T cells for mixed lymphocyte 
reactions. After 6 d of culture, cells were stained with CD4 and CD8 anti-
bodies and processed to flow cytometric analysis using the LSRII flow cy-
tometer. For MLRs with ex vivo–collected cells from carriers of HLA-B*35 
alleles,  CD1c+  and  CD141+  myeloid  dendritic  cells  were  isolated  from 
PBMCs  using  immunomagnetic  anti–BDCA-1  and  anti–BDCA-3  beads 
(Miltenyi Biotec) and immediately mixed with CFSE-labeled allogeneic T 
cells as described above. To analyze cytokine secretion, immature MDDCs 
were prepared and treated with tetramers as described above and then ma-
tured using 5 µg/ml CL097 (InvivoGen) in the presence of 5 µg/ml brefeldin 
A. After 20 h, cells were fixed and permeabilized, stained with antibodies 
recognizing intracellular IL-12p70 and IL-6, and processed to flow cytomet-
ric acquisition.
ILT4  knockdown.  siRNA  pools  specific  for  ILT4  message  (LILRB2   
ON-TARGETplus SMARTpool; ThermoF isher Scientific) or unspecific 
control siRNA message (Thermo Fisher Scientific) were used at concentra-
tions of 1 nmol/million cells. 106 MDDCs were suspended in 300 l Opti-
mem in the presence of siRNA and transferred to a 4-mm electroporation 
cuvette (Bio-Rad Laboratories). Cells were left on ice for 5 min, electropora-
ted (900 V, 0.75 msec square wave; Genepulser Xcell; Bio-Rad Laboratories), 
and transferred back to culture medium for another 16 h before analysis.
SPR  experiments. SPR experiments were performed using a BIAcore 
3000 instrument (BIAcore). Recombinant tetramers at a concentration of 
2mg/ml were individually immobilized (600 resonance units) to a CM5 sen-
sor chip (BIAcore) using standard amine coupling methods. Toxic shock 
syndrome toxin 1 (TSST-1) in an equivalent surface density was used as the 
control surface. Serial twofold dilutions of a recombinant protein dimer con-
taining two extracellular domains of human ILT4 fused to the Fc part of   
human IgG (R&D Systems) were injected over the sensor chip. After sub-
traction of background binding between ILT4 and TSST-1, the apparent 
steady-state equilibrium constant (KD) was determined by nonlinear regres-
sion analysis of SPR responses to the various concentrations of injected ILT4 
using the BiaEvaluation 4.1 software program (BIAcore).
Online  supplemental  materials. Fig. S1: Interactions between HLA-
B*3502  (Px)  complexes  and  the  inhibitory  myelomonocytic  recep-
tor  ILT4.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20091386/DC1.
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processes leading to the accelerated disease progression ob-
served in carriers of B*35-Px subtypes. Interestingly, the ac-
celerated course of HIV-1 infection mediated by B*35-Px 
subtypes starts during primary HIV-1 infection but remains 
continuously detectable during the entire disease course (Gao 
et al., 2005), which is more consistent with a negative effect 
mediated by interfering with immunoregulatory mechanisms 
rather than with the targeting of specific CTL epitopes or the 
evolution of characteristic viral escape variants. Moreover, a 
worsening of HIV-1 disease outcomes by activation of inhibi-
tory immunoreceptor signaling is well in line with the re-
cent recognition of the significant roles of other inhibitory 
immunoregulatory receptors, such as PD-1 (Day et al., 2006; 
Trautmann et al., 2006), in HIV-1 pathogenesis.
In a recent study we have shown that in the setting of a 
shared HLA class I molecule, recognition of peptide–MHC 
class I complexes by ILT4 can critically depend on the se-
quence of the presented CTL epitopes (Lichterfeld et al., 
2007). Other investigators have recently extended this finding 
by  identifying  lipid  antigen–specific  interactions  between 
CD1d and ILT4 (Li et al., 2009). Here, we show that presen-
tation of identical CTL epitopes by closely related HLA sub-
types can similarly have an important influence on the binding 
affinity of peptide–MHC class I complexes to ILT4, and on 
the functional profile of dendritic cells. Collectively, these 
data show that both viral and host genetics can impact den-
dritic cell function through interactions with the immuno-
regulatory receptor ILT4 and provide a new perspective to 
understanding  the  molecular  mechanisms  by  which  HLA 
class I alleles can impact HIV-1 disease progression. The spe-
cific  manipulation  of  interactions  between  peptide–MHC 
class I complexes and myelomonocytic MHC class I recep-
tors on dendritic cells may represent an attractive therapeutic 
strategy to improve HIV-1 disease outcomes in clinical set-
tings. Moreover, ILT4-mediated immunoregulatory proper-
ties of peptide–MHC class I complexes need to be considered 
in the design of HIV-1 vaccines.
MATERIALS AND METHODS
Patients. HIV-1–infected individuals with chronic HIV-1 infection were   
recruited from the Massachusetts General Hospital in Boston. Hemophiliac 
HIV-1–infected carriers of HLA-B*35 alleles were recruited from the Multi-
center Hemophilia Cohort Study. All subjects gave written informed consent 
to participate, and the study was approved by the Institutional Review Boards 
of the Massachusetts General Hospital and the National Cancer Institute.
Flow cytometry. PBMCs were stained with tetramers (obtained from the 
National Institutes of Health Tetramer Core Facility) for 5 min at room 
temperature before being incubated with PE-Cy7–labeled HLA-DR anti-
bodies, APC-labeled CD11c antibodies, and a cocktail of PE-labeled lineage 
antibodies. For ILT4 blocking assays, cells were incubated with a polyclonal 
ILT4-specific antibody (R&D Systems) for 30 min at 37°C before being 
stained with tetramers. Cells were then fixed and acquired on a flow cyto-
meter (model LSRII; BD).
Functional dendritic cell assays. MDDCs were prepared as described 
previously (Lichterfeld et al., 2007). 2 × 108 PBMCs were plated in 5% pooled 
human serum medium, and incubated for 60 min at 37°C to adhere mono-
cytes. Adherent monocytes were propagated in the presence of 50 µg/ml   2966 Divergent binding of HLA-B*35 alleles to ILT4 | Huang et al.
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